A 25-gene classifier predicts overall survival in resectable pancreatic cancer
Abstract Background Pancreatic carcinoma is one of the most lethal human cancers. In patients with resectable tumors, surgery followed by adjuvant chemotherapy is the only curative treatment. However, the 5-year survival is 20%. Because of a strong metastatic propensity, neoadjuvant chemotherapy is...
Main Authors: | David J. Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora Poizat, Jean-Luc Raoul, Jean-Robert Delpero, Vincent Moutardier, Daniel Birnbaum, Emilie Mamessier, François Bertucci |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12916-017-0936-z |
Similar Items
-
Validation and comparison of the molecular classifications of pancreatic carcinomas
by: David J. Birnbaum, et al.
Published: (2017-11-01) -
Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
by: David Jérémie Birnbaum, et al.
Published: (2019-04-01) -
<i>XPO1</i> Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
by: David Jérémie Birnbaum, et al.
Published: (2019-04-01) -
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study
by: Jonathan Garnier, et al.
Published: (2020-03-01) -
WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
by: Alexandre deNonneville, et al.
Published: (2021-09-01)